-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
-
Summary
-
Allogene Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from 2018 to 2023.
- Allogene Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2024 was -$55.9M, a 16.1% increase year-over-year.
- Allogene Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was -$238M, a 7.81% decline from 2022.
- Allogene Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was -$221M, a 19.3% decline from 2021.
- Allogene Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2021 was -$185M, a 60.6% decline from 2020.
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Growth (%)